XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer

Hepato-Gastroenterology

Volumn 59, Issue 120, 2012, Pages 2635-2639

  Berk, Veli ^a   Ozdemir, Nuriye ^b   Ozkan, Metin ^a   Aksoy, Sercan ^b   Turan, Nedim ^c   Inal, Ali ^d   Balakan, Ozan ^e   Yasar, Nurgul ^f   Unal, Olcun Umit ^g   Benekli, Mustafa ^c   Durnali, Ayse ^h   Colak, Dilsen ⁱ   Sonmez, Ozlem Uysal ^h  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e GAZIANTEP UNIVERSITY   (Turkey)

^f Kartal Training and Research Hospital ^*  (Turkey)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h ANKARA ONCOLOGY HOSPITAL   (Turkey)

ⁱ Yildirim Beyazit Training and Research Hospital   (Turkey)

Author keywords

5 fluorouracil; Capecitabine; Oxaliplatin; Pancreatic cancer

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; REPEATED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TURKEY;

EID: 84871234387     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12181     Document Type: Article

References (23)

1. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
2. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15:2403-2413.
3. Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (bsc) versus oxaliplatin, folinic acid and 5-fluorouracil (off) plus bsc in patients for second-line advanced pancreatic cancer: A phase iii-study from the german conko-study group. Eur J Cancer 2011; 47:1676-1681.
4. Xiong HQ, Varadhachary GR, Blais JC, et al.: Phase 2 trial of oxaliplatin plus capecitabine (xelox) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046-2052.
5. Tsavaris N, Kosmas C, Skopelitis H, et al.: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase ii study. Invest New Drugs 2005; 23:369-375.
6. Shukuya T, Yasui H, Boku N, et al.: Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: A retrospective study. Jpn J Clin Oncol 2010; 40:1135-1138.
7. Maeda S, Motoi F, Onogawa T, et al.: Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: A retrospective study. Int J Clin Oncol 2011; 16:539-545.
8. Cereda S, Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 2008; 20:509-512.
9. Katopodis O, Polyzos A, Kentepozidis N, et al.: Second-line chemotherapy with capecitabine (xeloda) and docetaxel (taxotere) in previously treated, unresectable adenocarcinoma of pancreas: The final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67:361-368.
10. Ko AH, Dito E, Schillinger B, et al.: Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: Results of a phase ii study. Cancer Invest 2008; 26:47-52.
11. Carvajal RD, Tse A, Shah MA, et al.: A phase ii study of flavopiridol (alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 2009; 9:404-409.
12. Burtness B: Her signaling in pancreatic cancer. Expert Opin Biol Ther 2007; 7:823-829.
13. Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al.: Pancreas microenvironment promotes vegf expression and tumor growth: Novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 2001; 81:1439-1451.
14. Brell JM, Matin K, Evans T, et al.: Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009; 76:270-274.
15. Ignatiadis M, Polyzos A, Stathopoulos G, et al.: A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006; 71:159-163.
16. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007; 25:1960-1966.
17. Boeck S, Vehling-Kaiser U, Waldschmidt D, et al.: Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: An interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'arbeitsgemeinschaft internistische onkologie'. Anticancer Drugs 2010; 21:94-100.
18. Kindler HL, Niedzwiecki D, Hollis D, et al.: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group b (calgb 80303). J Clin Oncol 2010; 28:3617-3622.
19. O'Reilly EM, Niedzwiecki D, Hall M, et al.: A cancer and leukemia group b phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (calgb 80603). Oncologist 2010; 15:1310-1319.
20. Wolpin BM, Hezel AF, Abrams T, et al.: Oral mtor inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27:193-198.
21. Yoo C, Hwang JY, Kim JE, et al.: A randomised phase ii study of modified folfiri.3 vs. modified folfox as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658-1663.
22. Pelzer U, Arnold D, Reitzig P, et al.: First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: A multicenter phase II trial by the conko-study group. Cancer Chemother Pharmacol 2011; 68:1173-1178.
23. Gasent Blesa J, Alberola Candel V, Giner Marco V, et al.: Phase ii trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (ox) and capecitabine (cp) J Clin Oncol 2009; 27:e15561.